WASHINGTON DC (September 24, 2018) – Today Dana Mariani is joining the Association for Accessible Medicines (AAM) Policy and Strategic Alliances team as Director, Policy.
Prior to joining AAM, Dana was part of a cross-functional Project Management Organization team at Guidehouse (formerly the public sector arm of PwC), supporting the Centers for Medicare and Medicaid (CMS) Quality Payment Program (QPP). Before that, she held positions at CareMetx in Bethesda, MD, and AAM member Lupin Pharmaceuticals in Baltimore, MD.
Dana is an MBA candidate at American University’s Kogod School of Business. She holds an BA from Johns Hopkins University and an MSPH from the Johns Hopkins Bloomberg School of Public Health.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.